ブックタイトルHealth Manegement for Female Athletes Ver.3

概要

Health Manegement for Female Athletes Ver.3

29. Rechichi C et al. Oral contraceptive phase has no effect on endurance test. Int J Sports Med, 29,277-281, 2008.30. Zderic TW et al. Glucose kinetics and substrate oxidation during exercise in the follicular andluteal phases. J Appl Physiol, 90, 447-453, 2001.31. Peters C and Burrows M. Androgenicity of the progestin in oral contraceptives does not affectmaximal leg strength. Contraception, 74, 487-491, 2006.32. Ekenros L et al. Oral contraceptives do not affect muscle strength and hop performance in activewomen. Clin J Sport Med, 23, 202-207, 2003.33. Giacomoni M et al. Influence of the menstrual cycle phase and menstrual symptoms on maximalanaerobic performance. Med Sci Sports Exerc, 32, 486-492, 2000.34. Rechichi C and Dawson B. Effect of oral contraceptive cycle phase on performance in team sportplayers. J Sci Med Sport, 12, 190-195, 2009.35. Bushman B et al. Anaerobic power performance and the menstrual cycle: eumenorrheic and oralcontraceptive users. J Sports Med Phys Fitness, 46,132-137, 2006.36. Renstrom P et al. Non-contact ACL injuries in female athletes: an International OlympicCommittee current concepts statement. Br J Sports Med, 42, 394-412, 2008.37. Heitz NA et al. Hormonal changes throughout the menstrual cycle and increased anterior cruciateligament laxity in females. J Athl Train, 34, 144-149, 1999.38. Park SK et al. Alterations in knee joint laxity during the menstrual cycle in healthy women leadsto increases in joint loads during selected athletic movements. Am J Sports Med, 37, 1169-1177,2009.39. Dragoo JL et al. Relaxin receptors in the human female anterior cruciate ligament. Am J SportsMed, 31, 577-584,2003.40. Dragoo JL et al. Prospective correlation between serum relaxin concentration and anteriorcruciate ligament tears among elite collegiate female athletes. Am J Sports Med, 39, 2175-2180,2011.41. Dragoo JL et al. Trends in serum relaxin concentration among elite collegiate female athletes. IntJ Womens Health, 19, 19-24, 2011.42. Nose-Ogura S et al. Oral contraceptive therapy reduces serum relaxin-2 in elite female athletes. JObstet Gynaecol Res, 43, 530-535, 2017.43.プリンシプル産科婦人科学１婦人科編.メジカルビュー, 106, 2014.44.プリンシプル産科婦人科学１婦人科編.メジカルビュー, 241, 2014.45. Mountjoy M et al. The IOC consensus statement: beyond the Female Athlete Triad--RelativeEnergy Deficiency in Sport (RED-S). Br J Sports Med, 48, 491-497, 2014.46. De Souza MJ et al. 2014 Female Athlete Triad Coalition Consensus Statement on Treatment andReturn to Play of the Female Athlete Triad: 1st International Conference held in San Francisco,California, May 2012 and 2nd International Conference held in Indianapolis, Indiana, May 2013,Br J Sports Med, 48, 289, 2014.47. Joy E et al. 2016 update on eating disorders in athletes: A comprehensive narrative review with afocus on clinical assessment and management. Br J Sports Med, 50, 154-162, 2016.48. Loucks AB et al. Luteinizing hormone pulsatility is disrupted at a threshold of energy availabilityin regularly menstruating women. J Clin Endocrinol Metab, 88, 297-311, 2003.49. Tenforde AS et al. Association of the Female Athlete Triad Risk Assessment Stratification to theDevelopment of Bone Stress Injuries in Collegiate Athletes. Am J Sports Med, 45, 302-310, 2017.50. Goolsby MA. Bone Health in Athletes. Sports Health, 9, 108-117, 2017.51. Mallinson RJ et al. Current perspectives on the etiology and manifestation of the "silent"component of the Female Athlete Triad. Int J Womens Health, 6, 451-467, 2014.193